Author(s):
Rishabh Aggarwal, Anuj Nautiyal, Yogesh Joshi
Email(s):
rishabhpharma001@gmail.com
DOI:
10.52711/2231-5659.2023.00042 
Address:
Rishabh Aggarwal, Anuj Nautiyal, Yogesh Joshi
Department of Pharmacy Practice, Shri Guru Ram Rai University, Patel Nagar, Dehradun, Uttrakhand, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 3,
Year - 2023
ABSTRACT:
In the late 1950s and the beginning of the 1960s, thalidomide was a medication that was frequently used to relieve nausea in pregnant women. Thalidomide treatment was shown to cause severe birth abnormalities in thousands of children in the 1960s. Thalidomide was an effective treatment for leprosy and later multiple myeloma, even though its usage was outlawed in the majority of nations at the time. Thalidomid treatment of pregnant leprosy patients has continued to result in deformities in rural areas of the world without major medical surveillance measures. Understanding of molecular targets is being improved through research into the mechanisms of thalidomide action. Safer medications might be created with a deeper understanding of these molecular targets. The thalidomide tragedy marked a turning point in toxicity testing because it compelled American and international regulatory agencies to create systematic toxicity testing protocols. In addition, the use of thalidomide as a developmental biology tool resulted in significant advancements in our understanding of the biochemical mechanisms underlying limb development. It is fitting to review the lessons learnt from the 1960s thalidomide disaster in honour of the Society of Toxicology's 50th anniversary, which also happens to be the same year that thalidomide was removed from the market.
Cite this article:
Rishabh Aggarwal, Anuj Nautiyal, Yogesh Joshi. Thalidomide - The Disastrous Drug. Asian Journal of Research in Pharmaceutical Sciences. 2023; 13(3):241-7. doi: 10.52711/2231-5659.2023.00042
Cite(Electronic):
Rishabh Aggarwal, Anuj Nautiyal, Yogesh Joshi. Thalidomide - The Disastrous Drug. Asian Journal of Research in Pharmaceutical Sciences. 2023; 13(3):241-7. doi: 10.52711/2231-5659.2023.00042 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2023-13-3-10
REFERENCES:
1. https://www.heathergoodwin1/the safety profile of thalidomide.
2. Jump up Stolberg SG (17 July 1998). "Thalidomide Approved to Treat Leprosy, With Other Uses Seen". New York Times. Retrieved 8 January 2012.
3. https://www.KatieStrong/the-thalidomid- saga
4. World Health Organization (2019). "World Health Organization model list of essential medicines: 21st list 2019“.
5. "FDA Approval for Thalidomide". National Cancer Institute. R Sneader W (2005). Drug discovery: a history (Rev. and updated ed.). Chichester: Wiley. p. 367 etrieved 8 January 2012.
6. Campbell, Denis. "'Wonder drug' left babies with deformed limbs." The Guardian. 29 July 2009. "Thalidomide: The Fifty Year Fight (no longer available)".
7. "The National Advisory Council (NAC)". The Thalidomide Trust. Archived from the original on 21 January 2011. Retrieved 2 July 2020. 15 May 2014. Retrieved 13 September2015.
8. "International Drug Monitoring: The Role of National Centers" (PDF) Retrieved February 27, 2015."Preparing for a Safety Inspection" (PDF). Steve Jolley. 2011. Retrieved January 4, 2016.
9. Essentials of Medical Pharmacology 8th edition
10. Current Challenges in Pharmacovigilance: Pragmatic Approaches 2001 Geneva.
11. "The Importance of Pharmacovigilance - Safety Monitoring of Medicinal Products: Chapter 2 - A Short History of Inv 'The Times' online November 5, 2006 11) ^ Database Involvement in Drug Safety Monitoring by WHO".